Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

RockyTSTH Aug. 31 at 3:17 AM

OPTION WATCHLIST 8/30/2026 $CVX - "Oil Giant Chevron Is Said To Be In Talks To Expand In Venezuela; Stock up in overnight market. High watch for $210.92 break for a new all time highs. Above that we can see $220 and $235. Oil stock on high watch this week. $VLO- Stock making new all time highs. Stock in a strong uptrend. Looking for calls as long as $350 holds for a move towards $375 and higher. Oil stocks are in great demand. $AAPL- Stock in a steady uptrend. Generally runs into new iphone launches. Looking for calls above $320 for a move towards $323 top of the trendline and $333 gap fill. If $320 fails we can see a retest of $312 bottom of the trendline. $JNJ- Stock in a steady uptrend and close to all time highs. High watch for calls above $270 for a move towards $275 and $285 possible $300. Key support at $260. $ADBE - Stock broke long term weekly resistance at $275 . Looking for calls above $292 for a move towards $300 and $325. For breakout continuation.

0 · Reply

Duncan74 Aug. 31 at 2:46 AM

$BMY $JNJ $MRK $SLS If you think the auction is only about GPS maintenance, you are completely missing the SLS009 CDK9 hammer. The data room isn't just a clinical file cabinet. It’s a structural playground where SLS009 solves every single pipeline crisis Big Pharma is facing. JNJ’s Phase 3 bleximenib faces severe resistance because leukemia cells ramp up MCL-1 survival proteins. SLS009 is engineered specifically to downregulate and destroy MCL-1, giving JNJ the ultimate combination booster BMS’s current AML lines rely on venetoclax, but patients inevitably relapse. SLS009 has fully matured data proving it forces deep, clean remissions in patients who completely failed venetoclax. Merck needs SLS009 to clear out immune-suppressive myeloid barriers, priming the field for a massive Keytruda combination monopoly. Sellas owns a closed-loop rescue canopy. SLS009 forces the remission, and GPS locks the maintenance vault.

0 · Reply

Duncan74 Aug. 31 at 2:39 AM

$SLS $MRK $BMY $JNJ Let the three giants fight it out to see who writes the biggest upfront cash/stock check for a total oncology monopoly. This is a textbook bidding collision. 🔥Look at the corporate battle lines: 1. BMS: Must defensively protect its AML maintenance crown (Onureg) from JNJ's threatening Phase 3 cAMeLot-2 trials. Buying Sellas blocks JNJ and secures their monopoly. 2. JNJ: Slashed early R&D by 42%. Their lead asset bleximenib is stuck in a narrow 15% mutation niche. They must buy Sellas’s universal WT1 platform to capture the other 85% of AML patients. 3. Merck: Pipelines are dangerously top-heavy after Phase 1 starts tripled. Facing a massive patent cliff, they desperately need advanced Phase 3 anchors like GPS to pair with Keytruda and extend their oncology dominance. 🧬🚀

0 · Reply

StocktwitsNews Aug. 31 at 2:29 AM

SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger $SLS $AZN $JNJ $XBI https://stocktwits.com/news/equity/markets/sls-healthcare-execs-aml-drug-game-changer-final-trial-trigger/cZYyW7URJrN

0 · Reply

DidYouReadThis Aug. 30 at 7:03 PM

$JNJ $LLY $NVO $SNY #music #songs #commercials #tempo #bpm

0 · Reply

Dean3326 Aug. 30 at 3:41 PM

$JNJ $SLS I want to apologize to JNJ for cross-posting… I did not realize when I reshared that it would post to the original pages and not just the one I was commenting on. Generally, I don’t cross-post. I realize I’m doing it again now, but that is because I think this message wouldn’t make sense without the context.

0 · Reply

KenFaulkenberry Aug. 30 at 2:46 PM

$$JNJ Johnson & Johnson (JNJ) Stock Analysis (Dividend King) Johnson & Johnson is known for its defensive qualities, reliable dividends, and exposure to long-term healthcare growth trends. Its focus on innovation and leading positions in both pharma and medical devices offer a solid foundation for continued earnings power. For conservative, income-oriented investors, JNJ is often seen as a core blue-chip holding that provides stability and moderate growth. Is the stock price a Buy, Sell, or Hold? What is the Intrinsic Value of Johnson & Johnson (JNJ)? https://dividendvaluebuilder.com/johnson-johnson-jnj-stock-analysis/

0 · Reply

Hannibal_Smith Aug. 30 at 10:53 AM

$SLS I mean… it doesn’t get simplier … 1 share $JNJ for 1 share SLS. Done deal. 😎

5 · Reply

Dean3326 Aug. 30 at 7:34 AM

$JNJ $SLS

1 · Reply

Juhanialainen Aug. 30 at 7:30 AM

$SLS Looks like the cancer vaccine space is going to get similar hype on us like the quantum sector had few years back. $MRNA $MRK $JNJ

0 · Reply

China approves J&J's oral psoriasis pill, says drugmaker

Aug 24, 2026, 7:12 PM EDT - 6 days ago

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Aug 24, 2026, 6:33 PM EDT - 6 days ago

US FDA expands approval for J&J's drug for rare blood disorder

Aug 24, 2026, 12:20 PM EDT - 6 days ago

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

2026-08-19T22:09:27.000Z - 11 days ago

Analysts Back Dividend Aristocrats JNJ and LIN Ahead of Q3 Earnings

LIN

2026-08-17T10:16:04.000Z - 13 days ago

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

ISRG

Aug 13, 2026, 11:15 PM EDT - 17 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Aug 10, 2026, 4:27 PM EDT - 20 days ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

2026-08-07T19:33:43.000Z - 23 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

CVX WMT

Aug 6, 2026, 6:23 PM EDT - 24 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

Aug 4, 2026, 4:05 PM EDT - 26 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Aug 4, 2026, 8:45 AM EDT - 26 days ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 3, 2026, 8:00 AM EDT - 27 days ago

Johnson & Johnson Transcript: Investor update

Aug 2, 2026, 8:00 AM EDT - 4 weeks ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Jul 30, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 29, 2026, 6:13 PM EDT - 4 weeks ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 5:42 PM EDT - 4 weeks ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:38 PM EDT - 4 weeks ago

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:28 PM EDT - 4 weeks ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 12:01 PM EDT - 4 weeks ago

Explainer: Can J&J finally put the talc litigation behind it?

Jul 28, 2026, 4:31 PM EDT - 4 weeks ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 12:26 PM EDT - 4 weeks ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 1:03 AM EDT - 4 weeks ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 12:31 AM EDT - 4 weeks ago

J&J offers $5.5bn to settle baby powder lawsuits

Jul 27, 2026, 9:29 PM EDT - 4 weeks ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 6:47 PM EDT - 4 weeks ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:31 PM EDT - 4 weeks ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 5:45 AM EDT - 4 weeks ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

$TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma$

Jul 23, 2026, 8:30 AM EDT - 5 weeks ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 22, 2026, 4:33 PM EDT - 5 weeks ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 7:21 AM EDT - 5 weeks ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:00 AM EDT - 5 weeks ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 21, 2026, 6:30 PM EDT - 5 weeks ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Jul 16, 2026, 8:11 AM EDT - 6 weeks ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:00 AM EDT - 6 weeks ago

DePuy Synthes Acquires Expanding Innovations™

Jul 15, 2026, 12:09 PM EDT - 6 weeks ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 6 weeks ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 6 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 6 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:25 AM EDT - 6 weeks ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 6 weeks ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 6 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 9, 2026, 1:00 PM EDT - 7 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 7 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 7 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 2 months ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 25, 2026, 5:00 AM EDT - 2 months ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 2:03 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

RockyTSTH Aug. 31 at 3:17 AM

0 · Reply

Duncan74 Aug. 31 at 2:46 AM

0 · Reply

Duncan74 Aug. 31 at 2:39 AM

0 · Reply

StocktwitsNews Aug. 31 at 2:29 AM

0 · Reply

DidYouReadThis Aug. 30 at 7:03 PM

$JNJ $LLY $NVO $SNY #music #songs #commercials #tempo #bpm

0 · Reply

Dean3326 Aug. 30 at 3:41 PM

0 · Reply

KenFaulkenberry Aug. 30 at 2:46 PM

0 · Reply

Hannibal_Smith Aug. 30 at 10:53 AM

$SLS I mean… it doesn’t get simplier … 1 share $JNJ for 1 share SLS. Done deal. 😎

5 · Reply

Dean3326 Aug. 30 at 7:34 AM

$JNJ $SLS

1 · Reply

Juhanialainen Aug. 30 at 7:30 AM

$SLS Looks like the cancer vaccine space is going to get similar hype on us like the quantum sector had few years back. $MRNA $MRK $JNJ

0 · Reply

Juhanialainen Aug. 30 at 7:28 AM

$JNJ so when are you going to buy Sellas Life Sciences out?

1 · Reply

grandehefe Aug. 30 at 6:51 AM

$JNJ $SLS

0 · Reply

MalonePosty Aug. 30 at 6:49 AM

$JNJ $SLS

0 · Reply

Juhanialainen Aug. 30 at 6:41 AM

$SLS Nice big pharma discussion on LinkedIn. Really nice indeed. $JNJ

4 · Reply

z_guy Aug. 29 at 7:56 PM

$LEGN I’m so pissed with those bastards at $JNJ right now I don’t even care if $LEGN had an offer at $20/share as long as the don’t sell to JNJ and screw them

2 · Reply

Duncan74 Aug. 29 at 4:49 PM

$SLS $MRK $JNJ Big Pharma is in a massive pipeline crisis, and they desperately need Sellas. Inside the VDR under strict NDAs, the industry is split in two: 🏢 CAMP A: THE SCALERS (Merck/AZ) Pipelines are top-heavy and near-term revenue engines are stalling. They NEED advanced Phase 3 oncology anchors right now to protect market share. 🧬 CAMP B: THE STREAMLINERS (J&J/Roche) Internal discovery engines are completely OFF after slashing early R&D. They MUST buy external, de-risked assets because they outsourced innovation. Why is management holding through this strict SEC Quiet Period? To completely eliminate the risk-discount before the 80th REGAL event unblinds. Forget complicated CVR milestone nonsense—we want a straight, heavy Upfront Cash + Liquid Stock buyout for immediate monetization. Let them fight it out to see who writes the biggest upfront check for a total monopoly. SELLAS is not desperate. The BP facing patent cliff is.

1 · Reply

vermigli Aug. 29 at 3:46 PM

I love dividend growth stocks because its like I get a raise every year just for holding. TTM Growth Rates (according to Seeking Alpha): $SPG 5.39% $MRK 5.04% $PEP 4.74% $CVX 4.49% $JNJ 4.38%

1 · Reply

Quantumup Aug. 28 at 5:08 PM

Guggenheim (a/o 8/26) reit'd Top Pick $SYRE at Buy-$130 after Spyre announced topline results for the Ph II SKYWAY-RA program where the magnitude of effect didn't meet SYRE's internal bar to justify prioritizing the SPY072 monoTx. PTGX - $JNJ $ABVX ABBV MRK TVRD Here's what Guggenheim said in its note: https://x.com/Quantumup1/status/2093385178164908159?s=20

0 · Reply

Bull_shift Aug. 28 at 4:06 PM

$JNJ why is this holding so well? $SPY $XBI

0 · Reply

SellasgpsCurativeBAT11 Aug. 28 at 2:44 PM

$ABBV $AZN $JNJ $PFE $SLS Merger Monday’s. Biotech Contrarian Indicators flashing big time today. ✌️🙏❤️‍🩹

0 · Reply

Outcomes Aug. 28 at 1:28 PM

$MRNA $MRK $PFE $JNJ .....how could I forget to copy this group!?

0 · Reply

SellasgpsCurativeBAT11 Aug. 28 at 12:24 PM

$ABBV $AZN $JNJ $PFE $SLS All the Repositioners, traders will be left on the sidelines when the T1 halt hits. Shorts are burying themselves deeper and deeper before liquidation 🔥 ✌️🙏❤️‍🩹

0 · Reply

Market Cap	645.95B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	24.47
Forward PE	22.89
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	5,766,400
Avg Vol	7,933,392
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	33%
Beta	0.24
Analysts	Strong Sell
Price Target	$276.29